bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice
Authors: Jing Wei , Chen Ying , Lu Lei , Hu Xiangui , Shao Chenghao , Zhang Yijie , Zhou Xuyu , Zhou Yingqi , Wu Lang , Liu Rui , Fan Kexing , Jin Gang
Published: April 2023

PDF - 177K, The effect of MSCs on human and murine NK cells activation. Human and mouse NK cells were stimulated by recombinant human or murine IL-15 (5ug/ml) for 24 hours, in the presence or absence of MSCs. CD69 and CD107a expressions on NK cells were detected by FACS. In addition, the effect of MSC-IL-15 on CD69 and CD107a expressions of mouse NK cells was also detected.
Supplementary Methods, Figure Legends from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 116KB
Table S-1 from 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation
Authors: Kovács Krisztina , Decatur Christina , Toro Marcela , Pham Dien G. , Liu Huaping , Jing Yuqi , Murray Timothy G. , Lampidis Theodore J. , Merchan Jaime R.
Published: April 2023

Table S-1. Effects of bFGF and VEGF on 2-DG's cellular transport in endothelial cells.
Supplementary Figure 4 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 81KB, in vitro PLX4032.
Supplementary Figure 2 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 73KB, PK.
Supplementary Figure 1 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 529KB, in vitro culture.
Supplementary Figure Legend from V-ATPase Inhibition Regulates Anoikis Resistance and Metastasis of Cancer Cells
Authors: Schempp Christina M. , von Schwarzenberg Karin , Schreiner Laura , Kubisch Rebekka , Müller Rolf , Wagner Ernst , Vollmar Angelika M.
Published: April 2023

PDF - 86K, Legends for Supplementary Figures 1 through 10.
Supplementary Figures 1 to 4 from Inhibition of Insulin-like Growth Factor–Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade
Authors: Martin Janet L. , de Silva Hasanthi C. , Lin Mike Z. , Scott Carolyn D. , Baxter Robert C.
Published: April 2023

PDF - 1625K, Supplementary Figure 1: IGFBP-3 does not stimulate EGFR phosphorylation in the absence of EGF. Supplementary Figure 2: Western blots showing SphK1 translocation and IGFBP-3 dependence in SphK1 translocation. Supplementary Figure 3: CyQuant cell proliferation assay of cells treated with gefitinib and SKi-II. Supplementary Figure 4: Effect of combined gefitinib and SKi-II on activation of signaling intermediates.
Supplementary Figure Legend from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Authors: Andersen Nicholas J. , Nickoloff Brian J. , Dykema Karl J. , Boguslawski Elissa A. , Krivochenitser Roman I. , Froman Roe E. , Dawes Michelle J. , Baker Laurence H. , Thomas Dafydd G. , Kamstock Debra A. , Kitchell Barbara E. , Furge Kyle A. , Duesbery Nicholas S.
Published: April 2023

PDF file - 70K
Supplementary Figures 1 through 15 from PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential
Authors: Cristóbal Ion , Manso Rebeca , Rincón Raúl , Caramés Cristina , Senin Clara , Borrero Aurea , Martínez-Useros Javier , Rodriguez María , Zazo Sandra , Aguilera Oscar , Madoz-Gúrpide Juan , Rojo Federico , García-Foncillas Jesús
Published: April 2023

PDF - 2988K, Supplementary Figure 1. Levels of immunoprecipitated PP2A from lysates of 21 CRC patients used in PP2A phosphatase assays (1D6 antibody). Supplementary Figure 2. Quantification of PP2A activity in CRC patients with normal mucosa and tumor samples (FL-309 antibody); * P < 0.05; ** P < 0.01; N: normal mucosa; T: tumor sample. Supplementary Figure 3. Levels of immunoprecipitated PP2A from lysates of 21 CRC patients used in PP2A phosphatase assays (FL-309 antibody). Supplementary Figure 4. Comparison between normal PPP2R1B sequence and silent alterations at codons 72 (A) and 391 (B) found in two CRC patients. The position altered is indicated by an arrow. Supplementary Figure 5. Western blot analysis of PPP2R2A and PPP2R5E in 21 CRC patients. Supplementary Figure 6. Quantification of PP2A activity using the 1D6 and FL-309 antibodies and western blot analysis of PP2A, CIP2A and SET in 7 CRC cell lines; * P < 0.05; ** P < 0.01; N1-2, normal tissue. Supplementary Figure 7. FTY720 treatment induces a PP2A activation. (A) Treatment with OA inhibits the FTY720-induced PP2A activity in RKO and LoVo cells. (B) Levels of immunoprecipitated PP2A (FL-309 antibody) from the RKO and LoVo lysates used in the phosphatase assays. Supplementary Figure 8. Analysis of cell viability in SW480, HT-29 and DLD-1 cells after FTY720 treatment. Supplementary Figure 9. Optical microscope images showing changes in morphology and cell viability after FTY720 treatment in RKO and DLD-1 cells. Supplementary Figure 10. Colony forming ability of HT-29 and DLD-1 cells untreated or FTY720-treated alone or in combination with okadaic acid. Supplementary Figure 11. Western blot showing PP2A, AKT and ERK1/2 phosphorylation and expression after FTY720 treatment in HT-29 and SW480 cells. Supplementary Figure 12. Western blot analysis of CIP2A, c-MYC, SET and PP2A expression after FTY720 treatment in RKO and LoVo cells. Supplementary Figure 13. MTS assays showing the effect of FTY720 and 5-FU (A), SN-38 (B) or LOHP (C) alone or in combination in DLD-1 cells. Supplementary Figure 14. MTS assays showing the effect of FTY720 and 5-FU (A), SN-38 (B) or LOHP (C) alone or in combination in HT-29 cells. Supplementary Figure 15. Effects of FTY720 on proliferation and apoptosis in a total of 5 sets of human samples, including normal mucosa and colorectal tumor. Each row represents an effect on expression of the paired control and FTY720 treated samples, and each column, a single IHC marker, including Ki-67 and cleaved caspase 3. Downregulation of expression is displayed in green, upregulation in red, and no effect in black.
Supplementary method and figure legends from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

Supplementary method and figure legends
Supplementary Materials and Methods from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

This documents contains the materials and methods of experiments described in supplementary data
Supplementary figure 6 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

Abundance of IL6 and COX2 in NSCLC cells and TPCA-1 inhibits their transcription.
Supplementary figure 5 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

TPCA-1 blocks cell cycle in G2/M in HCC827 cells.
Supplementary Figure S4 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

The IGF-Trap blocks IGF-I and IGF-II mediated functions in vitro
Supplementary Figure S2 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

The native sIGFIR decoy protein blocks IGF-I and IGF-II mediated functions in vitro
Supplementary Figure S1 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

Production and characterization of native, sIGFIR
Supplementary figure 1 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

TPCA-1 inhibits STAT3 phosphorylation.
Supplementary Materials and Methods and Supplementary Figures 1-3 from AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models
Authors: Bush Tammy L. , Payton Marc , Heller Scott , Chung Grace , Hanestad Kelly , Rottman James B. , Loberg Robert , Friberg Gregory , Kendall Richard L. , Saffran Douglas , Radinsky Robert
Published: April 2023

Supplementary Materials and Methods; Supplementary Figure 1: Effects of AMG 900 on nuclear morphology and centrosome features are consistent with aurora-B inhibition in MDA-MB-231 cell line; Supplementary Figure 2: Elevated expression of ABC transporter gene ABCB1 and ABCB4 in MDA-MB-231 (F11) PTX-r cell line; Supplementary Figure 3: Cell-cycle profiles of TNBC cell lines treated with paclitaxel or ixabepilone.
Supplementary Figure 7 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 7: Schematic representation that summarizes the proposed mechanism of action of CBS9106.
Supplementary Figure 6 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 6: Inhibitors of autophagy do not interfere with the efficacy of low dose MLN4924. HCT116 cells are treated with CBS9106 (100 nM), MLN4924 (50 nM or 1 microM) or 3-MA (5 mM) alone or in combination for 24 hours. Protein levels of CRM1, CulNEDD8, p53, HIF-1alpha, p70S6 Kinase (S6K), phospho-Thr389 p70S6 Kinase (p-S6K), LC3-I/II, p62, and beta-actin are determined by western blot analysis. The measured band density was normalized relative to that of the control sample, with the control value set to 1. Antibodies against HIF-1alpha (3716), S6K (2708), p-S6K (9234), or p62 (8025) were obtained from Cell Signaling Technology.
Supplementary Table 2 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Authors: Guo Qie , Lan Peixiang , Yu Xin , Han Qiuju , Zhang Jian , Tian Zhigang , Zhang Cai
Published: April 2023

PDF - 128K, Table S2. Sequences of primers used for PCR analysis.
Supplementary Figure 4 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Authors: Guo Qie , Lan Peixiang , Yu Xin , Han Qiuju , Zhang Jian , Tian Zhigang , Zhang Cai
Published: April 2023

PDF - 39K, Figure S4. TLR7 inhibition markedly decreased dual vector enhanced percentage and activation of tumor-infiltrating lymphocytes. The hepatoma-bearing mice were treated with bi-functional vector with or without co-administration of TLR7 inhibitor. The percentages and activation of NK, CD4+T and CD8+T cells in tumor-infiltrating sites were detected by flow cytometry. Data are representative or means (plus or minus) SD of three independent experiments.
Supplementary Figure 2 from βIII-Tubulin Regulates Breast Cancer Metastases to the Brain
Authors: Kanojia Deepak , Morshed Ramin A. , Zhang Lingjiao , Miska Jason M. , Qiao Jian , Kim Julius W. , Pytel Peter , Balyasnikova Irina V. , Lesniak Maciej S. , Ahmed Atique U.
Published: April 2023

Morphology and proliferation of knockdown cells.
Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 2. Hexokinase II RNA and IHC data
Supplementary Table S2 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Table S2: Primers used for genotyping of mouse models. Forward and Reverse primers used for genotyping Apf fl/fl and Brca2/p53 mice during the breeding program
Supplementary Table 3 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

Shelf-life of lyophilized 50% cholesterol DOPC-PEG-siRNA nanoliposomes stored at 4oC.
Supplementary Figure S5 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S5: Biodistribution analysis of nanoparticles using MRI and confocal and live imaging in mammary models
Supplementary Figure S4 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S4: Immunoblot analysis of oncoprotein targets using knockdown and mimic probes of microRNAs
Supplementary Figure S3 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S3: Toxicity studies of the nanoparticle in different organs.
Supplementary Figure S2: Cytotoxicity assays on different cell lines from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S2: Cytotoxicity assays on different cell lines. In vitro cytotoxicity assay
Supplementary Figure 2 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

In vitro characterization of liposomal formulations.
Supplementary Figure Legends from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Supplementary Figure Legends
Suppl Table 4 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Table 4. Antitumor Activity of Orally Administered TAK-733 Against A375 Melanoma Tumor Xenografts in Female Athymic Nude Mice
Suppl Table 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Table 3. TAK-733 AUC Summary A375 tumor bearing female nude mouse
Supplementary Table S1 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Table S1: (A) Oncomine database analysis of RRM2 expression between ER-positive and ER-negative breast cancer patients (25-29). (B) GEO database analysis of RRM2 expression between relapse free survival and no relapse free survival in breast cancer who received the tamoxifen as an adjuvant therapy for 5 years (30-34).
Supplementary Figure S6 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S6: Effect of Didox treatment on cell motility on MCF-7 RRM2 overexpressing breast cancer cells.
Suppl Table 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Table 1. IC50 Value Matrix
Supplementary Figure S5 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S5: Cell viability was measured with varying concentrations of (A) tamoxifen and (B) Didox.
Suppl Figure 6 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 6. Genomic Analyses of PDTX MB1374 Treated to Resistance
Supplementary Figure S4 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S4: Didox cooperates with tamoxifen to reduce cell proliferation.
Suppl Figure 5 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 5. Immunoblot of Effector Proteins in Tumors from PDTX Mice Treated with TAK-733
Suppl Figure 4 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 4. Representative PDTX Model MB1255 Treated with Vehicle or TAK-733
Supplementary Figure S3 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S3: Didox resensitizes RRM2 overexpressing and TamR cells to tamoxifen induced cell death.
Suppl Figure 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 3. Immunoblot of Effector Proteins and Markers of Apoptosis in Melanoma Cell Lines
Supplementary Figure S1 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S1: Transient expression of RRM2 modulates tamoxifen sensitivity in MCF-7 and T-47D breast cancer cell lines.
Suppl Figure 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 2. Immunoblot Analysis of Effector Proteins in Melanoma Cell Lines
Supplementary Figure S2 from Targeted Silencing of MLL5β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers
Authors: Nin Dawn Sijin , Yew Chow Wenn , Tay Sun Kuie , Deng Lih-Wen
Published: April 2023

Supplementary Figure S2: Pixel density analysis of E6 and E7 protein expression.
Supplementary figure 4 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary figure 4. GDC0941 effect on cell cycle
Supplementary figure 3 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary figure 3. Correlation of PI3K mutation, amplification, PI3K score, and mTOR score with sensitivity to GDC0941
Supplementary figure 2 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary figure 2. Representative FISH data
Supplementary Figure Legends from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure Legends
Supplementary figure 1 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary figure 1. Genetic alterations in the PIK3CA, PTEN, AKT, MTOR, and HRAS genes from 279 HNSCC tumors from the TCGA.
Supplementary Figure 5 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure 5: The specificity of RAV-18 to ADAM-9 protease activity
Supplementary Figure 4 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure 4: In vivo treatment of RAV-18.
Supplementary Figure 2 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure 2: Efficiency of siRNA transfection against ADAM-9, -10 and -17 in 3 gastric cancer cells.
Supplementary Figure 1 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure 1: Transcription level of ADAM9 in gastric cancer cell lines.
Supplementary Figure 1 from Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Authors: Onstenk Wendy , Kraan Jaco , Mostert Bianca , Timmermans Mieke M. , Charehbili Ayoub , Smit Vincent T.H.B.M. , Kroep Judith R. , Nortier Johan W.R. , van de Ven Saskia , Heijns Joan B. , Kessels Lonneke W. , van Laarhoven Hanneke W.M. , Bos Monique M.E.M. , van de Velde Cornelis J.H. , Gratama Jan W. , Sieuwerts Anieta M. , Martens John W.M. , Foekens John A. , Sleijfer Stefan
Published: April 2023

Examples of EpCAM and MCAM staining in primary tumor tissues from core needle biopsies taken before start of neoadjuvant chemotherapy
Supplementary Figure S7 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S7. Immunohistochemistry of PCNA
Supplementary Table 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure S4 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S4. Tryptophan emission fluorescence
Supplementary Figure S3 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S3. Protein purity
Supplementary Table 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Table 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Data from MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
Authors: Zhong Haihong , Fazenbaker Christine , Breen Shannon , Chen Cui , Huang Jiaqi , Morehouse Christopher , Yao Yihong , Hollingsworth Robert E.
Published: April 2023

Supplementary Data. Supplemental Table S1: Summary of MEDI-573 IC50 on the proliferation of sarcoma cell lines with or without exogenously added IGF-1 or IGF-2. Supplemental Figure S1: Effect of MEDI-573 in combination with AZD2014 on SJSA-1 tumor growth in vivo.
Supplementary Table 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Table S1. Top upregulated and downregulated canonical pathways and genes following treatment with AZD5363. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

MCF7 and MCF7-LTED cells were treated {plus minus} AZD5363 for 24-hours and RNA was submitted to microarray analysis.
Supplementary Table 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
S4. Effect of AZD5363 on the expression of endogenous ER genes by qRT-PCR. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

Cells lines were treated with the combinations stated above for 24-hours, RNA was extracted and cDNA synthetised. mRNA analysis was performed by RT-qPCR using taqman oligos described in the material and methods. Error bars represent {plus minus} SEM. *p<0.05; **p<0.01; ***p<0.001.
Supplementary Table 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure Legends from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure Legends from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
S1. Antiproliferative effect of escalating doses of AZD5363 in endocrine sensitive and resistant cell lines {plus minus} estrogen or androstenedione. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

Cells were treated in absence or presence of exogenous E2 (0.01nM), 1�S or androstenedione and increasing concentrations of AZD5363. Treatments were performed at day 1 and day 3 after seeding. After 6 days of treatment, cell viability was analyzed by using a cell titre-glo assay. Data are expressed as fold-change relative to vehicle control. Error bars represent {plus minus} SEM.
Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
Authors: Erice Oihane , Smith Michael P. , White Rachel , Goicoechea Ibai , Barriuso Jorge , Jones Chris , Margison Geoffrey P. , Acosta Juan C. , Wellbrock Claudia , Arozarena Imanol
Published: April 2023

Supplementary Figure 5. A, Colony formation assay on WM98.1 clones expressing an empty vector (vector) or MGMT (MGMT) treated with TMZ with or without veliparib (ABT). B, GI50s of the same WM98.1 clones treated with MMS with our without olaparib veliparib. PF50 values are also shown. D, GI50s of the 10 melanoma cell lines treated with MMS with our without olaparib veliparib. PF50 values are also shown. E, MGMT in vitro activity assays. Recombinant MGMT was incubated with increasing concentrations of olaparib, veliparib or lomeguatrib
Supplementary Figure 4 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
Authors: Erice Oihane , Smith Michael P. , White Rachel , Goicoechea Ibai , Barriuso Jorge , Jones Chris , Margison Geoffrey P. , Acosta Juan C. , Wellbrock Claudia , Arozarena Imanol
Published: April 2023

Supplementary Figure 4. A, Western-blot showing the expression levels of the MMR enzymes MSH2, MLH1 and MSH6 in NET cell lines. B, GI50s for glioblastoma (GBM), pancreatic neuroendocrine (NET) and colorectal (CRC) cancer cell lines treated with TMZ with our without olaparib. PF50 values are also shown.
Supplementary Figure 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure 2 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
Authors: Erice Oihane , Smith Michael P. , White Rachel , Goicoechea Ibai , Barriuso Jorge , Jones Chris , Margison Geoffrey P. , Acosta Juan C. , Wellbrock Claudia , Arozarena Imanol
Published: April 2023

Supplementary Figure 2. A,Effect 0.25μM olaparib on the proliferation of 12 melanoma cell lines. B, GI50s for TMZ of 12 melanoma cell lines treated with or without olaparib. PF50s values are also shown. C, Colony formation of 6 MGMT+ve and 6 MGMT-ve melanoma cell lines treated with TMZ in the presence or absence of olaparib.
Supplementary Figure 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure 4 from Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Authors: Schlaepfer Isabel R. , Rider Leah , Rodrigues Lindsey Ulkus , Gijón Miguel A. , Pac Colton T. , Romero Lina , Cimic Adela , Sirintrapun S. Joseph , Glodé L. Michael , Eckel Robert H. , Cramer Scott D.
Published: April 2023

Supplementary figure 4: Palmitate supplementation decreases the spliced/unspliced XBP-1 ratio: LNCaP cells were treated over 48 hours with etomoxir and and with or without 100uM palmitate conjugated to albumin. Supplements Figure 4A.
Figure S3 from Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
Authors: Tummala Ramakumar , Lou Wei , Gao Allen C. , Nadiminty Nagalakshmi
Published: April 2023

Immunohistochemical staining to verify the effects of quercetin and enzalutamide on their molecular targets is shown.
Sup Figure S3 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S3. Micronuclei frequency but not doubling time nor AsiDNA cell uptake or activation of H2AX phosphorylation, are predictive biomarker for sensitivity to AsiDNA. Spearman correlation between AsiDNa efficiency (AsiDNA EC50, ÂµM), and : (A) the AsiDNA uptake (Cy5.5-AsiDNA, MFI) ; (B) the LDL-receptor expressed at the cell membrane (LDL-R, MFI), and (C) the phosphorylation of H2AX histone variant (ï�§-H2AX, MFI and ï�§-H2AX, % positive respectively) and (D) Micronuclei frequency of the different cells lines (expressed as the percentage of cells with micronuclei) and (E) the cell lines doubling time (hours). P values are shown.
Figure S2 from Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
Authors: Tummala Ramakumar , Lou Wei , Gao Allen C. , Nadiminty Nagalakshmi
Published: April 2023

Synergy between quercetin and enzalutamide with effects on AR signaling is shown.
Supplementary Materials and Methods from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Additional details of antibodies, reagents, and methods used in this manuscript.
Supplementary Figure 7. Immunofluorescent localization of Fas and p62. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

MM1.S cells were left untreated or treated with Selinexor and Carfilzomib (CFZ; 50 nm each) overnight. Cells were then processed as described for immunofluorescence microscopy using anti-Fas mouse monoclonal antibody and anti-p62 rabbit polyclonal antibody and appropriate fluorophore-conjugated secondary antibodies. Cell surface Fas does not co-localize with p62-containing aggregates, supporting the notion that caspases and p62 localize to intracellular membranes.
Supplementary Data from Modeling of Patient-Derived Xenografts in Colorectal Cancer
Authors: Katsiampoura Anastasia , Raghav Kanwal , Jiang Zhi-Qin , Menter David G. , Varkaris Andreas , Morelli Maria P. , Manuel Shanequa , Wu Ji , Sorokin Alexey V. , Rizi Bahar Salimian , Bristow Christopher , Tian Feng , Airhart Susan , Cheng Mingshan , Broom Bradley M. , Morris Jeffrey , Overman Michael J. , Powis Garth , Kopetz Scott
Published: April 2023

Association between surgical specimen size and rate of PDX establishment.
Supplementary Figure 5. Anti-tumor response of all groups of mice treated with carfilzomib or selinexor alone and in combination. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Changes in mean tumor volume of all groups of mice treated with selinexor and carfilzomib, alone and in combination.
Supplementary Figure 3. Western blot analysis of myeloma PC derived from three relapsed/refractory patients treated with selinexor and carfilzomib, alone and in combination. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Plasma cells from patients that have failed on treatment regimens that have included proteasome inhibitors, immunomodulatory drugs, and DNA damaging agents were purified from fresh bone marrow aspirates and treated with selinexor and carfilzomib.
Supplementary Figure 2. Representative images used in aggresome analysis. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Representative images of RPMI 8226 cells used for calculation of aggresome formation in response to selinexor and carfilzomib treatment.
Supplemental figure legends from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental figure legends - detailed text